---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-048196"
form_type: "8-K"
ticker: "MGTX"
cik: "0001735438"
company_name: "MeiraGTx Holdings plc"
filed_at: "2026-04-24T23:59:59+00:00"
generated_at: "2026-05-15T04:13:01.218994+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# MeiraGTx closes initial $200M Hologen collaboration; Hologen to own 70% of neuro JV

## Summary
- Completed initial closing of strategic collaboration with Hologen on April 20, 2026; Hologen provided $200M upfront cash payment.
- Hologen to fund remaining portion of upfront via post-completion share purchases, ultimately owning 70% of HNAI and minority stake in MeiraGTx Manufacturing.
- Collaboration covers AAV-GAD for Parkinson's disease, AAV-BDNF for genetic obesity disorders, and proprietary CNS delivery device.
- MeiraGTx Neuro UK retains 30% of HNAI; Hologen gets exclusive option to buy up to 40% of MeiraGTx Manufacturing shares within 12 months.

## SEC filing metadata
- accession: 0001104659-26-048196
- form_type: 8-K
- ticker: MGTX
- cik: 0001735438
- company_name: MeiraGTx Holdings plc
- filed_at: 2026-04-24T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1735438/000110465926048196/0001104659-26-048196-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1735438/000110465926048196/mgtx-20260420x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-048196
- JSON: https://secwatch.observer/filing/0001104659-26-048196.json
- Plain text: https://secwatch.observer/filing/0001104659-26-048196.txt

## Source-grounded claims
- claim_id: cca1797bc46e79733e992ca91fea620145fc92f9
  claim: MeiraGTx Holdings plc entered into Collaboration Agreement with Hologen Neuro AI UK Limited and Hologen Limited and Hologen Neuro AI Limited (effective 2026-04-20).
  evidence_excerpt: the Company, MeiraGTx Neuro UK, MeiraGTx Neuro I, LLC, a Delaware limited liability company (“MeiraGTx Neuro US”), Hologen, HNAI and Hologen Neuro AI UK Limited, a private company limited by shares incorporated in England (“HNAI UK”), entered into the Collaboration and License Agreement (the “Collaboration Agreement”), for the research, development, manufacture and commercialization of the Company’s (i) AAV-GAD investigational gene therapy for the treatment of Parkinson’s disease, AAV-BDNF investigational gene therapy for the treatment of genetic obesity disorders and other potential locally delivered genetic medicines to the central nervous system (the “Clinical Programs”) and (ii) proprietary device designed to effect the local delivery of a gene therapy product into the central nervous system or any topographic or subcutaneous tissue modification on the face and scalp, of humans or animals (the “Delivery Device”), in each case, in accordance with the terms and conditions of the Coll
  evidence_url: https://www.sec.gov/Archives/edgar/data/1735438/000110465926048196/0001104659-26-048196-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.